9 signals this week: 2 Clinical trials, 2 Bioequivalence, 5 Regulatory

Sponsors running India BA/BE studies under the export prior-intimation route (Form CT-05, G.S.R. 50(E)) get no new instructions this week, which means last week's filing checklist still applies without amendment.

Confirm your India BE study initiation workflow still cites Form CT-05 prior intimation and G.S.R. 50(E), nothing on the CDSCO IT-cell page this week changes either requirement, so a stale internal SOP is now the more likely error than a missed regulatory update.

The idea worth testing against your own QMS: can you name the last inspection-readiness or complaint-trend metric that changed a BD, partnership, or investor conversation, if not, quality data is still filed as compliance overhead, not evidence.

Pick one QMS metric, inspection finding rate, submission success rate, or complaint trend, and put it in front of a non-quality audience (BD, investor relations) this quarter as a test of whether it lands as a business signal.

Sponsors currently procuring point-solution AI trial tools alongside a Parexel contract should ask what ParexelAI actually replaces versus duplicates before the next contract renewal, the answer determines whether this saves a procurement cycle or adds a redundant one.

Before renewing or signing a Parexel CRO agreement, get ParexelAI's data governance and validation terms written into the quality agreement, "embedded AI" shifts the audit trail question from vendor management to CRO oversight, and the contract should say which.

USDM defines protocols as machine-readable structured data instead of PDF text, which is the precondition for any tool that claims to auto-populate a CTMS or EDC build from a protocol, if your vendor can't say whether it reads USDM, it's translating by hand.

Ask your EDC, CTMS, and regulatory-submission vendors directly whether they ingest USDM-structured protocols today or on a named roadmap date, "standards-aligned" without a USDM answer is not the same as USDM-compatible.

Comments on the RFI are due 29 May 2026; FDA says it "intends to disseminate final selection criteria in July and complete pilot selections in August", sponsors outside the first two have roughly two months to get infrastructure gaps on paper before the criteria lock.

Sponsors evaluating RTCT participation need a data architecture built for real-time review from protocol inception, FDA's own framing is that "with improvements in AI and data science, sponsors and trial sites have the opportunity to conduct real-time trials in a way that enhances safety monitoring and radically increases efficiency," which assumes streaming infrastructure exists before first patient in, not after.

Otavio Berwanger, chair of the network's International Registration Review Committee, framed the stakes directly: "Being part of the UK Registered Clinical Trials Unit (CTUs) Network isn't just about recognition; it genuinely strengthens how CTUs design and deliver trials", for a CTU chasing NIHR funding, registration is the prerequisite that quote is describing.

UK CTUs have until the 2027 effective date to close three specific gaps: RCT completion-and-publication tracking, a documented EDI framework, and PPI&E evidence that goes beyond named authorship, the network says it is also "broadening the way CTUs can evidence contribution beyond named authorship," so the PPI&E fix may be a documentation change, not a new programme.

The FAQ draws a hard boundary on scope: FDA states that "offering the device in other contexts (e.g., outside of the CMMI ACCESS model) would fall outside of the TEMPO pilot", a device can't ride TEMPO's enforcement discretion into a general-market launch.

Document your RWD collection plan, QMS evidence, and interim reporting cadence now, FDA says it expects manufacturers "to ultimately seek appropriate marketing authorization from the FDA, using the data collected during their participation in the pilot," meaning TEMPO data has to be 510(k)-submission-grade from day one, not just pilot-grade.

Any BE study in progress against a reference product ANVISA has since dropped or swapped on the list is exposed at submission, the agency's own language ties the list directly to registro (registration) and mudanças pós-registro (post-registration changes), not just to new filings.

Pull the 21 May 2026 LMR version and cross-check it against the reference product named in every open Brazil-bound BE protocol, record the list's publication date alongside the protocol approval date so a later ANVISA review can see which version applied when the study started.

This follows TGA's February 2026 guidance clarifying that software meeting the medical device definition must be on the ARTG, the compliance principles turn that definitional guidance into an enforcement priority, so an unregistered SaMD is now a named target, not a grey area.

Confirm ARTG registration status and software classification for every AI or software component marketed in Australia against TGA's post-February-2026 definition, validation evidence and intended-use documentation are the two items most likely to be requested if selected for the priority enforcement category.